Research

Found 141,973 articles

• Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

  3/21/2023

  Coya Therapeutics, Inc. today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.

• LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours

  3/21/2023

  LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announces exciting preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product.

• OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivity

  3/21/2023

  OcuSciences today announced a publication in Frontiers in Ophthalmology journal.

• Axalbion to Present Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

  3/21/2023

  Axalbion announced that it will present positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.

• Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

  3/21/2023

  Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome.

• Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham

  3/21/2023

  Diamond Therapeutics Inc. ("Diamond"), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce the FDA's authorization of the IND application submitted by collaborator Dr. Peter Hendricks.

• RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

  3/21/2023

  RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.

• MyClearStep, Powered by Shapa a Health-tech Company, has Announced an Exciting New Partnership With Top-Tier R1 Research Universities to Conduct Extensive Clinical Trials on Eating Disorders

  3/21/2023

  Health-tech company MyClearStep, powered by Shapa, has announced an exciting new partnership with top-tier R1 research universities to conduct extensive clinical trials on eating disorders.

• Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

  3/21/2023

  Quoin Pharmaceuticals Ltd. today announces the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients.

• Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  3/21/2023

  Vaccinex, Inc. today announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC), NCT05102721.

• Aviv Clinics Highlights New Hyperbaric Oxygen Therapy Study Bringing Hope to Fibromyalgia Patients

  3/21/2023

  Aviv Clinics is sharing the results of a new study that shows hyperbaric oxygen therapy is more effective than pharmaceutical treatment in fibromyalgia patients following traumatic brain injury.

• Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease

  3/21/2023

  Direct Biologics, LLC announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo ™ for the treatment of patients with medically refractory Crohn’s disease.

• CHOP Researchers Find Strong Adolescent-Parent Relationships Lead to Better Long-term Health Outcomes in Young Adults

  3/21/2023

  Researchers from Children's Hospital of Philadelphia have found that adolescents who report strong relationships with their parents have better long-term health outcomes.

• Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens

  3/21/2023

  Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk.

• Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

  3/21/2023

  Sensei Biotherapeutics, Inc. today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, in patients with solid tumors.

• BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

  3/21/2023

  BridgeBio Pharma, Inc. today announced the Company’s novel validated muscle tissue-based bioassay, which measures the amount of glycosylated ⍺DG in patients with LGMD2I.

• New Model N Study Finds Quality Channel Data Management Drives Performance

  3/21/2023

  Model N, Inc. released a new commissioned study by Forrester Consulting that shows how improved channel data management leads to better trust, collaboration, and bottom-line results.

• Invitae Announces Partnership with Epic to Streamline Genetic Testing

  3/21/2023

  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. 

• Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

  3/21/2023

  Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

• Feinstein Institutes researchers use novel imaging technology to study how the brain and body communicate

  3/21/2023

  Bioelectronic medicine researchers at The Feinstein Institutes for Medical Research have developed a new method for studying neural signals transmitted to the brain through the vagus nerve – the nerve that helps controls functions like heart rate, breathing and immune response.